Introduction to Health Economics

Why this matters in health economics

Money, staff, and time are finite. Health and care demand is effectively unlimited. So choices must happen. Each choice funds some patients while not funding others. Health economics exists to make choices visible, comparable, and defensible.

The stakes are high. Health spending is among the largest lines in most national budgets, funded from taxation, compulsory social insurance, private premiums, or families' own pockets. The decisions it governs are matters of life, disability, and dignity. The decisions often fall unequally across rich and poor.

When a decision is made badly — funding a marginal therapy while a cost-effective one goes without — the loss is not abstract. It is measured in avoidable deaths and suffering among the people who were crowded out, even though no one ever sees their names.

For a director, health economics is about accountability. It gives you a shared language for discussing value with clinicians, finance officers, regulators, and the public.

Core concepts

Scarcity is the starting axiom. Scarcity means that resources — money, clinicians, beds, operating-theatre hours, a patient's own time — are insufficient to satisfy all the wants that could lay claim to them. Scarcity is not the same as poverty; even the richest health systems are scarce, because the frontier of what medicine could do always outruns what any budget can do.

Opportunity cost is the concept that follows directly. The opportunity cost of a decision is the value of the best alternative it displaces. Spending a fixed budget on a new cancer drug has a cost measured not only in currency but in the health that the same money would have produced elsewhere — the hip replacements, mental-health sessions, or antenatal visits forgone. In a fixed-budget health system, opportunity cost is the true price of everything, and much of health economics is machinery for estimating it.

Efficiency is doing the most good with given resources — but the word has two distinct ideas. Economic efficiency splits into technical efficiency (producing a given output with the fewest inputs, or the most output from given inputs) and allocative efficiency (producing the mix of outputs that yields the greatest value to society). A hospital can be technically efficient — running lean, wasting nothing — while being allocatively wrong, delivering the wrong services superbly. Both matter, and they are not interchangeable.

Marginal analysis is how economists actually make these judgements. Marginalism asks not "is this service worthwhile?" but "is the next unit of it worth more than the same resources spent elsewhere?" The right question is rarely all-or-nothing. It is whether to screen at age 50 or 55, whether the tenth follow-up appointment adds as much as the first, whether one more percentage point of vaccination coverage justifies its rising cost. Value is found at the margin, and averages routinely mislead. When budgets shift, the right instrument is often programme budgeting and marginal analysis — comparing what an extra pound buys across competing uses.

Why health care is economically distinctive. Health economics is a separate field, rather than a corner of ordinary microeconomics, because health care violates the assumptions of a textbook market in systematic ways. Kenneth Arrow showed that pervasive uncertainty and unequal information make medical markets behave unlike markets for ordinary goods. Four features recur: demand is uncertain and often urgent; patients know far less than their clinicians, creating information asymmetry and an agency relationship in which the seller advises the buyer; third parties usually pay, blunting price signals; and health has consequences for others — vaccination protects the unvaccinated, antimicrobial resistance harms future patients — so private choices carry public effects.

The Williams "plumbing diagram." The most useful single map of health economics is the schematic drawn by the British economist Alan Williams. The schematic is known as the plumbing diagram because it shows how the field's topics feed into one another like connected pipes. It divides the discipline into eight interconnected boxes:

• A — What determines health? The wider influences — income, education, environment, behaviour — of which health care is only one, often not the largest.
• B — What is health, and what is it worth? Defining and valuing health outcomes, including measures such as the quality-adjusted life year (QALY) and the disability-adjusted life year (DALY).
• C — The demand for health care. How the need for health translates into demand for services, mediated by prices, insurance, and agency.
• D — The supply of health care. How services are produced — the costs, workforce, technology, and industrial structure of provision.
• E — Micro-economic evaluation at the treatment level. Comparing the cost and benefit of specific interventions; the home of cost-effectiveness analysis.
• F — Market equilibrium. How demand and supply interact through prices, waiting, and rationing when a conventional market clears imperfectly or not at all.
• G — Evaluation at the whole-system level. Judging entire systems on efficiency and equity, and comparing countries.
• H — Planning, budgeting, and monitoring. The instruments — budgets, payment methods, regulation, priority-setting — that steer the system.

The diagram is the book's skeleton. Boxes A–C map onto Part 1 (Foundations); boxes B and E map onto Part 2 (Evaluation and Evidence, especially Chapter 2.1 — Economic Evaluation); boxes F–H map onto Part 3 (Systems, Policy and Priorities). Whenever you feel lost in a health-economics argument, ask which box you are standing in.

The discipline's history and institutions. Health economics coalesced in the 1960s and 1970s. Arrow supplied the theory; the American economist Selma Mushkin framed health as an investment in human capital; Michael Grossman formalized that idea in his 1972 model of health as a durable capital stock (developed in Chapter 1.2 — Demand for Health and Healthcare); and figures such as Anthony Culyer and Alan Williams built the applied, evaluative tradition — "extra-welfarism" — that underpins much of today's practice. The field now has its own journals, its own methods, and, crucially, its own institutions. Health technology assessment (HTA) bodies apply health economics to real reimbursement decisions worldwide: England's National Institute for Health and Care Excellence (NICE), Germany's Institute for Quality and Efficiency in Health Care (IQWiG), Canada's drug agency, and Australia's Pharmaceutical Benefits Advisory Committee among them. Global bodies such as the World Health Organization (WHO) and the World Bank carry the same methods into low- and middle-income settings, and national coverage schemes such as India's Ayushman Bharat show the field operating at vast scale.

Best practices

1. Start from scarcity, not from need. Need is limitless and, on its own, a poor guide to action, because everything a health system might do meets some need. Begin instead by naming the fixed resource — this budget, this workforce, this year — and accept that funding one thing means not funding another. A plan that does not say what it displaces is not yet a plan.

2. Make the opportunity cost explicit in every proposal. For any spend, state what the same resources would otherwise achieve, in health terms wherever possible. The comparator is not "doing nothing" but the best displaced alternative. This single discipline prevents the most common error in health decision-making: judging an intervention against zero rather than against its rival claims on the budget.

3. Argue at the margin. Resist all-or-nothing framings. Ask whether the next unit — the next screening round, the next staffed bed, the next percentage point of coverage — is worth its cost, and recognize that the answer changes as you scale. Marginal thinking turns unwinnable "fund it or not" fights into tractable "how much" decisions.

4. Separate the two efficiencies before you claim either. Be explicit about whether you are asserting technical efficiency (this service is run leanly) or allocative efficiency (this is the right service to run). Conflating them lets a beautifully-run programme escape the harder question of whether it should exist at that scale at all.

5. Locate every question on the plumbing diagram. Before commissioning analysis, identify which of Williams' eight boxes you are in — determinants, valuation, demand, supply, treatment-level evaluation, equilibrium, system evaluation, or planning. Mixing boxes is a frequent source of muddled briefs, where a demand problem is answered with a supply study.

6. Name the health system when a claim is system-specific. Practices, prices, and thresholds differ across tax-funded, social-insurance, private-insurance, and out-of-pocket systems. State which system a claim belongs to — "in England, NICE…", "under Germany's social insurance…" — rather than presenting one country's arrangement as universal. The economics travels; the institutions do not (see Chapter 3.1 — Health Systems).

7. Distinguish health from health care. Box A of the plumbing diagram is a standing reminder that most of what determines health lies outside the clinic — income, housing, education, environment, behaviour. Treat health care as one input to health among several, and be wary of proposals that assume every health gain must be bought through services.

8. Prefer evidence to eloquence, and quantify where you honestly can. Health economics is a defence against decisions settled by confidence and seniority. Ask for the estimate, the comparator, and the uncertainty; where a number cannot be had, describe the pattern qualitatively rather than inventing precision. A transparent range beats a false point estimate.

9. Value outcomes in commensurable units, then respect their limits. Measures such as the QALY and the DALY let very different interventions be compared on one scale, which is what makes priority-setting possible. Use them — and remember they compress ethical judgements that some stakeholders will reject (see Chapter 2.1 — Economic Evaluation and Chapter 3.5 — Capabilities).

10. Treat equity as a first-class objective, not an afterthought. Efficiency tells you how to get the most health; it does not tell you whose health, or how fairly it is shared. State the distributive aim alongside the efficiency aim, and surface the trade-off between them rather than hiding it (see Chapter 3.4 — Equity).

11. Use health economics to structure disagreement, not to end it. The methods rarely produce a single incontestable answer; their value is in making assumptions, comparators, and value judgements visible so that reasonable people can argue about the right things. A model whose assumptions are exposed and contested has done its job even when the decision remains hard.

12. Signpost to the specialist chapter rather than half-teaching a method. This introduction gives you the vocabulary; the depth lives elsewhere. When a decision turns on how to build a model, appraise an econometric claim, or price a drug, go to the chapter that owns it rather than improvising the method from first principles.

Questions to discuss with your team

1. When we fund something new this year, what specifically will we stop doing — and can we name it? This question forces opportunity cost from slogan into practice. Most organizations can list what they want to add; few can say what they will displace, which is why budgets creep and the least-scrutinized existing services survive by inertia. The honest answer identifies a real comparator inside your own budget, not a rhetorical "efficiency saving" that never materializes. Watch for the tell-tale evasion of funding new activity from assumed future growth or one-off underspend. A mature team can point to the disinvestment that pays for each investment, and can explain why the displaced activity was worth less at the margin. If no one can answer, you are not yet doing health economics — you are doing wishful budgeting.

2. Are we chasing technical efficiency when our real problem is allocative — running the wrong things well? Organizations under financial pressure default to cost-cutting: trimming waste, squeezing unit costs, doing the same services more cheaply. That is technical efficiency, and it has a floor. The harder and often larger prize is allocative — shifting resources from low-value activity to high-value activity, which may mean stopping things that are run perfectly well. This question can be uncomfortable because it challenges services with strong internal champions and long histories. An honest discussion names at least one activity the organization does efficiently but should perhaps not do at all, and asks whether the savings programme is quietly protecting sacred cows while cutting muscle elsewhere.

3. Whose health are we optimizing, and who is being crowded out that we never see? Every funded decision has invisible losers — the patients whose care was displaced by the money spent elsewhere. Because they are statistical rather than identified, they exert no political pressure, while the beneficiaries of a new programme are visible, grateful, and often organized. This asymmetry systematically biases decisions toward the visible and away from the cost-effective. The question asks the team to reason explicitly about the crowded-out, and to decide whether any distributive aim — favouring the worst-off, a deprived region, a neglected condition — justifies departing from pure efficiency. An honest answer states both the efficiency logic and the equity logic, and admits where they pull apart, rather than pretending the two always coincide.

4. Which of our biggest arguments are actually "how much" questions we keep fighting as "yes or no"? Health decisions are habitually framed as all-or-nothing — fund the service or scrap it, screen the population or do not — when the real question is almost always the marginal one: how much, for whom, and up to what point. That framing matters because value is found at the margin, and the tenth unit of an activity rarely delivers what the first did; a programme worth running at modest scale can be wasteful when pushed to universal coverage. The tension is that all-or-nothing framings are politically convenient — they rally supporters and simplify the vote — while marginal framings force the harder, more honest bargaining over dose, threshold, and coverage. Concrete angles include naming the specific decision variable (the screening age, the number of staffed beds, the coverage percentage) and asking where the next unit stops earning its cost. An honest answer converts at least one of the team's stuck "fund it or not" disputes into a tractable question about the right quantity, and admits that the answer shifts as you scale. Where the marginal reasoning bites, the right instrument is often programme budgeting and marginal analysis — comparing what an extra pound buys across rival uses (see Chapter 3.3 — Rationing).

5. Are we reaching for a clinical service when the health gain we want is mostly made outside the clinic? Box A of the Williams plumbing diagram is a standing warning that most of what determines health — income, housing, education, environment, behaviour — lies beyond the reach of health care, yet organizations reflexively answer every health problem with a new service. The tension is real: health systems are funded, staffed, and held accountable for clinical activity, so a determinant-based intervention can be more cost-effective and still fall between the cracks because no one owns it or because its benefits arrive years later and outside the health budget. This question asks the team to test whether a proposed clinical spend is genuinely the best buy, or whether a non-clinical route — or a partner outside the health system — would produce more health per pound. Concrete angles include separating "health" from "health care" in the objective, and checking whether standard one-year return-on-investment tools understate a slow-burn prevention benefit. An honest answer names at least one candidate intervention that is not a service, and confronts the accountability gap that makes such options easy to ignore (see Chapter 1.5 — Determinants of Health).

6. When we disagree, what settles it here — the evidence, or the most senior and confident voice in the room? Health economics exists partly as a defence against decisions made by seniority and assertion, yet under time pressure most organizations default to exactly that, letting the loudest or most eminent advocate carry the day. The tension is that demanding the estimate, the comparator, and the uncertainty is slower and can feel like an affront to experienced colleagues who "just know" — while eloquence unchecked reliably funds the wrong things. This question asks the team to examine its own decision culture: are assumptions and comparators exposed for challenge, or asserted and waved through? Concrete angles include asking, for a recent decision, whether anyone could state the comparator and the range around the estimate, and whether a junior analyst could safely contest a director's claim. An honest answer admits where the organization has been settling arguments by confidence rather than evidence, and accepts that a transparent range beats a false point estimate even when it is less rhetorically satisfying. The goal is not to end disagreement but to structure it around contestable assumptions, so reasonable people argue about the right things.

In practice: a health economics example

The Ministry of Health of Solmara — a fictional middle-income country of about 30 million people, funding health from a mix of general taxation and a growing social-insurance scheme — faces a familiar squeeze. Its budget has risen, but demands have risen faster: an ageing population, a rising burden of diabetes and heart disease, and a newly-approved but expensive class of medicines whose manufacturers are lobbying hard for coverage. The minister wants "the best value for the nation's health," and asks a small analytics unit to bring order to competing bids.

The unit resists the temptation to evaluate each bid in isolation against "doing nothing," which would make almost every proposal look worthwhile. Instead it fixes the constraint: a defined incremental budget for the coming year, which it treats as the scarce resource whose opportunity cost every bid must beat. The framing question becomes not "is this drug effective?" but "does an extra unit of spending here produce more health than the same unit spent on the next-best alternative?" — marginal analysis applied to a real budget.

To keep the debate coherent, the unit maps each bid onto the Williams plumbing diagram. The expensive new medicines are a treatment-level evaluation question (box E) and are sent for cost-effectiveness analysis against existing therapies, expressed in cost per QALY. A rival proposal to expand community-based hypertension screening sits partly in box A — it is a determinant-of-health intervention whose benefits accrue slowly and partly outside the health system — and the unit flags that standard one-year return-on-investment tools will understate it, because the strokes averted fall years later. A third bid, to renegotiate how hospitals are paid, is a box-H planning question, not a treatment question at all, and is routed to a different team.

The analysis is uncomfortable in exactly the way it should be. The new medicines deliver real benefit but at a cost per QALY several times higher than the hypertension programme; funding them in full would displace enough primary-care activity to produce a net loss of health across the population, even though each treated patient visibly gains. The screening programme is more cost-effective but concentrated in wealthier districts with better clinics, raising an equity concern the efficiency numbers do not capture. The unit does not pretend the model settles the matter. It presents the minister with an explicit choice: the efficient allocation, the more equitable allocation, and the opportunity cost of moving between them — naming, as far as it can, the invisible patients each option crowds out. That transparency, not a single "right" answer, is the health economics doing its work.

Four sector lenses

Startup

A digital-health start-up feels scarcity as runway rather than budget, and its binding constraint is often evidence rather than money. Its temptation is to argue value against "doing nothing" — the status quo the product replaces — when the decision-maker who matters, a payer or health system, will judge it against the best existing alternative and its opportunity cost. The disciplined move is to identify, early and honestly, which box of the plumbing diagram the product sits in and what outcome it improves in commensurable terms, so that when a serious evaluation comes (see Chapter 5.2 — Digital Health Economics) the founders are not surprised by questions they could have asked themselves.

Small business

An established small provider — a GP partnership, a single clinic, a care home, or a small supplier — lives the economics of scarcity at close quarters, but as a steady-state operator spending its own money rather than a start-up burning investors' runway. Its budget is fixed and modest, so every decision to add a service, a session, or a member of staff visibly displaces another use of the same funds, making opportunity cost concrete rather than theoretical. The temptation here is to judge each purchase against doing nothing and to reason from average cost, when the honest question is marginal: does the next clinic session, the next piece of equipment, the next enrolled patient earn more than its rival claims on a small purse? Because such a provider usually operates within a larger system's rules — a national tariff, a commissioner's contract, an insurer's fee schedule — its distinctive discipline is to locate its decisions on the plumbing diagram and to accept the health system whose prices and thresholds it cannot itself set (see Chapter 3.1 — Health Systems). Its accountability is direct and personal: to its own patients or residents, and to the partners or owners whose income the same budget also funds.

Enterprise

A large hospital group, insurer, or provider network has the scale to be technically efficient and the inertia to be allocatively wrong. Its portfolio spans dozens of services with entrenched champions, and its real health-economics work is internal reallocation — shifting resource from low-value to high-value activity, which means disinvestment as well as investment. Programme budgeting and marginal analysis is the natural tool at this scale. The accountability is to a board and to members or patients, and the discipline is to apply the same marginal test across competing internal claims rather than funding the loudest.

Government

A ministry or national payer carries the widest accountability — to taxpayers, citizens, and the crowded-out — and the strongest reasons to make its reasoning explicit and legitimate. It sets the rules of the game: budgets, payment methods, coverage decisions, and the HTA institutions that apply health economics at national scale (NICE, IQWiG, and their counterparts). Its distinctive burden is equity: efficiency alone will not answer whose health to favour, and a government must defend its distributive choices in public (see Chapter 3.2 — Health Policy and Chapter 3.4 — Equity). Its distinctive risk is that visible beneficiaries out-shout invisible losers, biasing decisions away from cost-effectiveness.

Common failure modes

• Judging against "nothing" instead of the real alternative. Evaluating a proposal against a do-nothing baseline makes almost anything look worthwhile. Fix: always specify the best displaced alternative as the comparator.
• Confusing health with health care. Assuming every health gain must be bought through clinical services ignores box A of the plumbing diagram. Fix: consider determinants — income, environment, behaviour — as candidate interventions alongside services.
• All-or-nothing framing. Debating whether to fund a whole programme when the live question is how much of it. Fix: reframe at the margin — the next unit, not the whole.
• Mistaking technical for allocative efficiency. Cutting unit costs while leaving the wrong service mix untouched. Fix: ask separately whether the activity should exist at that scale, not just whether it is run leanly.
• Treating one country's rules as universal. Importing a threshold, price, or institutional arrangement without naming its system. Fix: state the system a claim belongs to and adapt the principle, not the number.
• False precision. Inventing point estimates to sound authoritative when the evidence supports only a range. Fix: describe the pattern qualitatively and show the uncertainty honestly.
• Ignoring the invisible losers. Counting the visible beneficiaries of a decision and never the crowded-out. Fix: reason explicitly about opportunity cost in health terms, and about equity.

Maturity model

Checklist

• The scarce resource (budget, workforce, time) for this decision is named and fixed.
• Each proposal states what it displaces — its opportunity cost — in health terms where possible.
• The question is framed at the margin (the next unit), not all-or-nothing.
• Technical and allocative efficiency are distinguished, and the right one is being addressed.
• Each question is located on a box of the Williams plumbing diagram before analysis is commissioned.
• System-specific claims name the health system they belong to.
• Outcomes are expressed in commensurable units (e.g. QALYs/DALYs) where appropriate, with limits acknowledged.
• Distributive aims are stated alongside efficiency aims, and any trade-off is made explicit.
• Figures are real and checkable, or described qualitatively; no invented precision.
• The decision routes method-heavy questions to the chapter or specialist that owns them.

Key sources

• Arrow, K. J. (1963), "Uncertainty and the Welfare Economics of Medical Care" — the founding paper establishing why medical markets differ from ordinary markets.
• Williams, A. — the "plumbing diagram" — the canonical map of health economics as eight interconnected topics; widely reproduced in textbooks and teaching material.
• Economics Network — Health Economics for Teachers — a university teaching curriculum whose module structure mirrors this field's map.
• Wikipedia — Health economics — a well-referenced overview of the discipline, its history, and its subfields.
• GOV.UK — Health economics: a guide for public health teams — a national exemplar of practitioner-facing health economics.
• Textbooks: Morris, Devlin, Parkin & Spencer, Economic Analysis in Health Care; Folland, Goodman & Stano, The Economics of Health and Health Care; Wonderling, Gruen & Black, Introduction to Health Economics.
• World Health Organization — health financing and health systems publications for worldwide practice.

References

1. Health economics — Wikipedia — https://en.wikipedia.org/wiki/Health_economics
2. Scarcity — Wikipedia — https://en.wikipedia.org/wiki/Scarcity
3. Opportunity cost — Wikipedia — https://en.wikipedia.org/wiki/Opportunity_cost
4. Economic efficiency — Wikipedia — https://en.wikipedia.org/wiki/Economic_efficiency
5. Marginalism — Wikipedia — https://en.wikipedia.org/wiki/Marginalism
6. Kenneth Arrow — Wikipedia — https://en.wikipedia.org/wiki/Kenneth_Arrow
7. Alan Williams (economist) — Wikipedia — https://en.wikipedia.org/wiki/Alan_Williams_(economist)
8. Selma Mushkin — Wikipedia — https://en.wikipedia.org/wiki/Selma_Mushkin
9. Anthony Culyer — Wikipedia — https://en.wikipedia.org/wiki/Anthony_Culyer
10. Quality-adjusted life year — Wikipedia — https://en.wikipedia.org/wiki/Quality-adjusted_life_year
11. Health technology assessment — Wikipedia — https://en.wikipedia.org/wiki/Health_technology_assessment
12. Information asymmetry — Wikipedia — https://en.wikipedia.org/wiki/Information_asymmetry
13. World Health Organization — Wikipedia — https://en.wikipedia.org/wiki/World_Health_Organization
14. Uncertainty and the Welfare Economics of Medical Care — Kenneth J. Arrow, American Economic Review (1963) — https://www.aeaweb.org/aer/top20/53.5.941-973.pdf
15. Health Economics for Teachers — Economics Network — https://economicsnetwork.ac.uk/health/teachers
16. Health economics: a guide for public health teams — GOV.UK — https://www.gov.uk/guidance/health-economics-a-guide-for-public-health-teams